COGT
Cogent BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts or a partnership deal could drive accelerated adoption of the drug candidate and multiple expansion; bull target assumes ~50% upside vs anchor with positive news.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical failure or need for additional financing would depress valuation; bear target reflects substantial dilution/negative readthroughs and a large drawdown.
Momentum
38
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.50 · Bull $12.75 · Bear $5.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $53.83
Why
Momentum38 · Δ7d -1.5
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
38
34% active weight
Current posture
7d trendFlat
Δ7d
-1.5
Δ21d
-30.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 37.9 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$5.6B
Beta
0.45
Shares Out
175.28M
P/E (TTM) · Derived
-12.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.42
Rev YoY
-
EPS YoY
+8.2%
Gross Margin
-
Op Margin
-
Net Debt
-$287.08M
Current Ratio
6.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology